Xiangdong Xue
xuexd@sjtu.edu.cn
Title / Position
Xiangdong Xue, PhD
Tenure track associate professor, Principal Investigator
Email: xuexd@sjtu.edu.cn
Lab homepage: https://www.x-mol.com/groups/xiangdong_xue
Google Scholar: https://scholar.google.com/citations?user=ksr8ZNsAAAAJ&hl=en
Address:
School of Pharmacy, Shanghai Jiao Tong University
800 Dongchuan Road, Minhang District, Shanghai, China, 200240
Xiangdong Xue, Ph.D., Associate Professor, Principal Investigator at School of Pharmacy, Shanghai Jiao Tong University. Dr. Xue got Ph.D degree from the National Center for Nanoscience and Technology, University of Chinese Academy of Sciences, under the supervision of Professor Xing-Jie Liang. Then, he started his postdoctoral career in the United States. From 2015 to 2020, Dr. Xue worked as a postdoctoral researcher at the Washington University in St. Louis and the University of California, Davis. Then, he joined Shanghai Jiao Tong University as a full-time faculty in December 2020. At present, Dr. Xue has published 46 high-level SCI papers with a total impact factor of over 400, and his papers have been cited more than 2000 times, with an H factor of 24. As the first or corresponding author, Dr. Xue has published 17 papers (total impact factor >180) in some decent journals, such as Nature Nanotechnology, Nature Communications, Advanced Materials, ACS Nano, Biomaterials, Advanced Functional Materials, Advanced Science, Journal of Controlled Release, Nano Research. Dr. Xue has applied 2 PCT international patents and 5 Chinese patents. Meanwhile, Dr. Xue has been recognized by the peers, he has been invited as reviewers of ~20 peer-reviewed journals, including Biomaterials, Advanced Sciences, Small, ACS Applied Material & Interface, Chemical Engineering Journal, Acta Biomaterialia, Journal of Controlled Release, Molecular Pharmaceutics.
Xue lab is newly established, so we are recruiting. Come and join us, we welcome scientists from different fields who are interested in combating cancer with advanced chemical, material, medicinal and biological technologies.
Research fields
o Intelligent small-molecule nanomedicine for cancer treatments
o Precise diagnosis of early-stage cancer with tunable MRI contrast agents and corresponding imaging techniques
o Immunoregulation and immunotherapy for the treatment of advanced metastatic cancer
1. Wang, Z.†; Xue, X.†; Lu, H.; He, Y.; Lu, Z.; Chen, Z.; Yuan, Y.; Tang, N.; Dreyer, C. A.; Quigley, L.; Curro, N.; Lam, K. S.; Walton, J. H.; Lin, T.-y.; Louie, A. Y.; Gilbert, D. A.; Liu, K.; Ferrara, K. W.; Li, Y., Two-way magnetic resonance tuning and enhanced subtraction imaging for non-invasive and quantitative biological imaging. Nature Nanotechnology 2020, 15, 482–490. IF=31.538. https://www.nature.com/articles/s41565-020-0678-5.pdf
2. Xue, X.†; Huang, Y.†; Bo, R.; Jia, B.; Wu, H.; Yuan, Y.; Wang, Z.; Ma, Z.; Jing, D.; Xu, X.; Yu, W.; Lin, T.-y.; Li, Y., Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nature Communications 2018, 9 (1), 3653. IF= 12.121.
https://doi.org/10.1038/s41467-018-06093-5
3. Xue, X.†; Zhao, Y.†; Dai, L.; Zhang, X.; Hao, X.; Zhang, C.; Huo, S.; Liu, J.; Liu, C.; Kumar, A.; Chen, W.-Q.; Zou, G.; Liang, X.-J., Spatiotemporal Drug Release Visualized through a Drug Delivery System with Tunable Aggregation-Induced Emission. Advanced Materials 2014, 26 (5), 712-717. IF= 27.398.
http://onlinelibrary.wiley.com/store/10.1002/adma.201302365/asset/adma201302365.pdf?v=1&t=iz0ldjzy&s=0153d6c3da81f55879576a5138e5f0795f045a2c
4. Xue, X.; Bo, R.; Qu, H.; Jia, B.; Xiao, W.; Yuan, Y.; Vapniarsky, N.; Lindstrom, A.; Wu, H.; Zhang, D.; Li, L.; Ricci, M.; Ma, Z.; Zhu, Z.; Lin, T.-y.; Louie, A. Y.; Li, Y., A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors. Biomaterials 2020, 257, 120234. IF=10.317. http://www.sciencedirect.com/science/article/pii/S0142961220304804
5. Xue, X.†; Huang, Y.†; Wang, X.; Wang, Z.; Carney, R. P.; Li, X.; Yuan, Y.; He, Y.; Lin, T.-y.; Li, Y., Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 2018, 161, 203-215. IF=10.317.
http://www.sciencedirect.com/science/article/pii/S0142961218300632
6. Xue, X.†; Jin, S.†; Zhang, C.; Yang, K.; Huo, S.; Chen, F.; Zou, G.; Liang, X.-J., Probe-Inspired Nano-Prodrug with Dual-Color Fluorogenic Property Reveals Spatiotemporal Drug Release in Living Cells. ACS Nano 2015, 9(3), 2729-2739. IF= 14.588. http://pubs.acs.org/doi/pdfplus/10.1021/nn5065452
7. Wang, Z.†; Xue, X.†; He, Y.; Lu, Z.; Jia, B.; Wu, H.; Yuan, Y.; Huang, Y.; Wang, H.; Lu, H.; Lam, K. S.; Lin, T.-Y.; Li, Y., Novel Redox-Responsive Polymeric Magnetosomes with Tunable Magnetic Resonance Property for In Vivo Drug Release Visualization and Dual-Modal Cancer Therapy. Advanced Functional Materials 2018, 1802159. IF=16.836.
https://onlinelibrary.wiley.com/doi/abs/10.1002/adfm.201802159
8. Xue, X.†; Jin, S.†; Li, Z.; Zhang, C.; Guo, W.; Hu, L.; Wang, P. C.; Zhang, J.; Liang, X.-J., Through-Bond Energy Transfer Cassette with Dual-Stokes Shifts for “Double Checked” Cell Imaging. Advanced Science 2017, 1700229. IF=15.840. https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.201700229
9. Yuan, Y.; Bo, R.; Jing, D.; Ma, Z.; Wang, Z.; Lin, T.-y.; Dong, L.; Xue, X.*; Li, Y.*, Excipient-free porphyrin/SN-38 based nanotheranostics for drug delivery and cell imaging. Nano Research 2020, 13, 503-510. IF=8.183.
https://link.springer.com/content/pdf/10.1007/s12274-020-2641-z.pdf
10. Yu, W.†; Xue, X.†; Ma, A.-H.; Ruan, Y.; Zhang, H.; Cheng, F.; Li, Y.; Pan, C.-X.; Lin, T.-Y., Self-Assembled Nanoparticle-Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition. Advanced Therapeutics 2020, 3, 2000032. IF=N/A.
https://onlinelibrary.wiley.com/doi/abs/10.1002/adtp.202000032
11. Xue, X.†; Ricci, M.†; Qu, H.; Lindstrom, A.; Zhang, D.; Wu, H.; Lin, T.-Y.; Li, Y., Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy. Journal of Controlled Release 2020. IF=7.727. http://www.sciencedirect.com/science/article/pii/S0168365920305848
12. Xue, X.; Lindstrom, A.; Qu, H.; Li, Y., Recent advances on small-molecule nanomedicines for cancer treatment. WIREs Nanomedicine and Nanobiotechnology 2019, 12 (3), e1607. IF=7.689.
https://onlinelibrary.wiley.com/doi/abs/10.1002/wnan.1607
13. Xue, X.; Lindstrom, A.; Li, Y., Porphyrin-Based Nanomedicines for Cancer Treatment. Bioconjugate Chemistry 2019, 30 (6), 1585-1603. IF=4.031.
https://doi.org/10.1021/acs.bioconjchem.9b00231
14. Yuan, Y.; He, Y.; Bo, R.; Ma, Z.; Wang, Z.; Dong, L.; Lin, T.-y.; Xue, X.*; Li, Y.*, A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 2018, 10 (46), 21634-21639. IF=6.895.
https://pubs.rsc.org/en/content/articlepdf/2018/nr/c8nr05141k
15. Yang, X.†; Xue, X.†; Luo, Y.; Lin, T.-y.; Zhang, H.; Lac, D.; Xiao, K.; He, Y.; Jia, B.; Lam, K. S.; Li, Y., Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy. Journal of Controlled Release 2017, 261, 297 - 306. IF=7.727.
http://www.sciencedirect.com/science/article/pii/S0168365917307228
16. Xue, X.; Xu, J.; Wang, P. C.; Liang, X.-J., Subcellular behaviour evaluation of nanopharmaceuticals with aggregation-induced emission molecules. Journal of Materials Chemistry C 2016, 4, 2719-2730. IF=7.059.
http://pubs.rsc.org/en/content/articlepdf/2016/tc/c5tc03651h
17. Xue, X. †; Zhao, Y. †; Zhang, X.; Zhang, C.; Kumar, A.; Zhang, X.; Zou, G.; Wang, P.; Zhang, J.; Liang, X.-J., Phenylboronic acid-functionalized magnetic nanoparticles for one-step saccharides enrichment and mass spectrometry analysis. Biophysics Report 2015, 1 (2), 61-70. IF=N/A.